What does CELC do?
Celcuity, based in Minneapolis, employs 55 staff and went public on September 20, 2017. Its lead candidate, gedatolisib, targets specific cancer pathways and is in trials for advanced breast and prostate cancer.
Headquarters
Minnesota, USA